91 related articles for article (PubMed ID: 21198717)
1. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
2. Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Leleu X; Kyriakou C; Vande Broek I; Murphy P; Bacon P; Lewis P; Gilet H; Arnould B; Petrucci MT
Blood Cancer J; 2017 Mar; 7(3):e543. PubMed ID: 28304402
[TBL] [Abstract][Full Text] [Related]
3. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.
Chen Y; Lairson DR; Chan W; Huo J; Du XL
J Manag Care Spec Pharm; 2017 Aug; 23(8):831-843. PubMed ID: 28737990
[TBL] [Abstract][Full Text] [Related]
5. Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis.
LeBlanc MR; Zhou X; Baggett CD; Tuchman SA; Jensen CE; Lichtman EI; Rubinstein SM
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38760283
[TBL] [Abstract][Full Text] [Related]
6. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
8. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Teitelbaum A; Ba-Mancini A; Huang H; Henk HJ
Oncologist; 2013; 18(1):37-45. PubMed ID: 23299776
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Brown RE; Stern S; Dhanasiri S; Schey S
Eur J Health Econ; 2013 Jun; 14(3):507-14. PubMed ID: 22572968
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
Kim MY; Sposto R; Swaika A; Asano H; Alamgir A; Chanan-Khan A; Ailawadhi S
Oncology; 2014; 87(4):224-31. PubMed ID: 25059308
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
Garrison LP; Wang ST; Huang H; Ba-Mancini A; Shi H; Chen K; Korves C; Dhawan R; Cakana A; van de Velde H; Corzo D; Duh MS
Oncologist; 2013; 18(1):27-36. PubMed ID: 23299777
[TBL] [Abstract][Full Text] [Related]
14. Total cost comparison in relapsed/refractory multiple myeloma.
Durie B; Binder G; Pashos C; Khan Z; Hussein M; Borrello I
J Med Econ; 2013; 16(5):614-22. PubMed ID: 23281721
[TBL] [Abstract][Full Text] [Related]
15. The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Messori A; Maratea D; Nozzoli C; Bosi A
Pharmacoeconomics; 2011 Apr; 29(4):269-85. PubMed ID: 21395348
[TBL] [Abstract][Full Text] [Related]
16. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.
Petrucci MT; Calabrese E; Levi A; Federico V; Ceccolini M; Rizzi R; Gozzetti A; Falco P; Lazzaro C; Martelli E; Boccadoro M; Lauria F; Liso V; Cavo M; Foa R
Tumori; 2013; 99(4):e193-202. PubMed ID: 24326862
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Lenalidomide-Plus-Dexamethasone in Multiple Myeloma Patients Who Have Received at Least One Prior Therapy: A South Korean Perspective.
Vandewalle B; Félix J; Almeida J; Valeska A; Yeo R
Value Health; 2014 Nov; 17(7):A736. PubMed ID: 27202638
[No Abstract] [Full Text] [Related]
18. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.
Lassalle A; Thomaré P; Fronteau C; Mahé B; Jubé C; Blin N; Voldoire M; Dubruille V; Tessoulin B; Touzeau C; Chauvin C; Loirat M; Lok A; Bourcier J; Lestang E; Mocquet R; Barbarot V; Moreau P
Ann Oncol; 2016 Feb; 27(2):314-8. PubMed ID: 26578729
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
Drugs; 2011 Mar; 71(5):625-49. PubMed ID: 21443285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
